Zobrazeno 1 - 10
of 841
pro vyhledávání: '"pimavanserin"'
Autor:
Yury P. Sivolap, Anna A. Portnova
Publikováno v:
Клинический разбор в общей медицине, Vol 5, Iss 8, Pp 6-11 (2024)
Disorders manifested by both neurological and mental disorders belong to the neuropsychiatric diseases. This category includes Alzheimer's disease, Parkinson's disease, Wernicke–Korsakoff syndrome, delirium tremens, catatonia and anti-NMDA receptor
Externí odkaz:
https://doaj.org/article/db4711c263e64b30a721b15ec2af92a2
Publikováno v:
Journal of Medical Sciences, Vol 44, Iss 3, Pp 103-110 (2024)
Psychosis in patients with dementia-related disorders has long been a challenging issue to be tackled by the medical fraternity. Although atypical antipsychotics (AP) are in use for the same reason, there has always been a question regarding their sa
Externí odkaz:
https://doaj.org/article/812a04b902ec4d8b8e190b943e50e178
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 7 (2024)
Aim: Real-world healthcare resource use (HCRU) burden among patients with Parkinson’s disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (other-AAPs) including quetiapine (QUE) in long term care (LTC) and n
Externí odkaz:
https://doaj.org/article/9968848d42864920aaff402d533200b7
Autor:
Nassef Hossam M., Ahmed Hoda A., Bashal Ali H., El-Atawy Mohamed A., Alanazi Tahani Y. A., Mahgoub Samar M., Mohamed Mahmoud A.
Publikováno v:
Reviews in Analytical Chemistry, Vol 43, Iss 1, Pp 157-62 (2024)
Externí odkaz:
https://doaj.org/article/acdafc222b7f4ca99fba7e33134ba6c6
Publikováno v:
Biomedicines, Vol 12, Iss 10, p 2317 (2024)
Objectives: Parkinson’s disease psychosis (PDP) is a prevalent non-motor symptom associated with Parkinson’s disease. The treatment options for PDP are limited, and its pharmacological management remains ambiguous. This study aimed to evaluate th
Externí odkaz:
https://doaj.org/article/6ee4b740be8d4660839745566dbf1f0a
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 1 (2023)
Aim: Risk of long-term care (LTC) admission (LTCA) associated with atypical antipsychotic (AAP) use among patients with Parkinson’s disease psychosis (PDP) is a major concern. However, no comparative studies have examined the differences in risk
Externí odkaz:
https://doaj.org/article/f6bb5ab4c50740d39d793aaaa8bcf65b
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115665- (2023)
Triple negative breast cancer (TNBC) poses a significant clinical challenge due to its lack of targeted therapy options and the frequent development of chemotherapy resistance. Metastasis remains a primary cause of mortality in late-stage TNBC patien
Externí odkaz:
https://doaj.org/article/8cc2f28596e749c89f2f7534c5b2432b
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol Volume 19, Pp 1303-1312 (2023)
Beatrice Heim, Marina Peball, Florian Krismer, Atbin Djamshidian, Klaus Seppi Department of Neurology, Medical University of Innsbruck, Innsbruck, AustriaCorrespondence: Beatrice Heim; Klaus Seppi, Department of Neurology, Medical University of Innsb
Externí odkaz:
https://doaj.org/article/959ffcc6d9954faaaf6eafcdd9f79968
Publikováno v:
Frontiers in Neuroscience, Vol 17 (2023)
BackgroundPimavanserin, a serotonin 5HT-2A receptor inverse agonist is the first-line, FDA-approved treatment of hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP), which occurs in up to 50% of PD patients. The neurobi
Externí odkaz:
https://doaj.org/article/e60d00e4ff5a4179b8ac217d3daa3d98
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.